1-20 of 929
Journal Article
ACCEPTED MANUSCRIPT
Bypassing the immunosuppressive effects of CA125/MUC16 via re-engineered rituximab (NAV-006) to improve its antitumor activity in vivo
Antibody Therapeutics, tbaf008, https://doi.org/10.1093/abt/tbaf008
Published: 24 April 2025
Journal Article
ACCEPTED MANUSCRIPT
A Review of Conjugation Technologies for Antibody Drug Conjugates
Antibody Therapeutics, tbaf010, https://doi.org/10.1093/abt/tbaf010
Published: 17 April 2025
Image
In vitro characterization of BA3011. (A) pH affinity ELISA. Bindin...
Published: 10 April 2025
Figure 1
In vitro characterization of BA3011. (A) pH affinity ELISA. Binding of BA3011 to human AXL at pH 6.0 (filled circles) and pH 7.4 (open circles) was determined by ELISA with a series of antibody concentrations as indicated. (B) pH range ELISA. Binding of BA3011 to human AXL at different pH values as
Image
BA3011 binding kinetics to human AXL at the indicated pH value measured by ...
Published: 10 April 2025
Figure 3
BA3011 binding kinetics to human AXL at the indicated pH value measured by SPR. (A) Representative sensorgrams for pH 6.0 (left), pH 6.5 (middle), and pH 7.4 (right). (B) Calculated binding kinetics of BA3011 to human AXL based on 3 independent experiments.
Image
BA3011 in vitro cytotoxicity assay. BA3011 in vitro cell ...
Published: 10 April 2025
Figure 4
BA3011 in vitro cytotoxicity assay. BA3011 in vitro cell killing of LCLC103H cells (A), DU145 cells (B), or AXL-negative 293-F cells (C) at pH 6.0 (solid lines) and pH 7.4 (dashed lines). Ctrl: B12-MMAE. (D) IC 50 values calculated from the inhibition curves from three independent experiments.
Image
In vivo cytotoxicity of BA3011. Cytotoxicity of BA3011 was tested ...
Published: 10 April 2025
Figure 5
In vivo cytotoxicity of BA3011. Cytotoxicity of BA3011 was tested in several cell-line derived tumor models in mice: (A) LCLC103H (lung cancer); (B) MiaPaCa (pancreatic cancer), and (C) DU145 (prostate cancer). Animals were dosed every 4 days (arrows) intravenously with BA3011 or buffer only (vehic
Image
Pharmacokinetic and toxicokinetic analysis of BA3011 in NHPs. (A) PK analys...
Published: 10 April 2025
Figure 6
Pharmacokinetic and toxicokinetic analysis of BA3011 in NHPs. (A) PK analysis for a single dose of BA3011 in cynomolgus monkeys. Plasma concentrations of total ADC, total antibody, and free MMAE in the serum of cynomolgus monkeys after a single dose of 3 mg/kg BA3011 (A) or repeat dosing on day 1 an
Journal Article
Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody–drug conjugate
Antibody Therapeutics, tbaf006, https://doi.org/10.1093/abt/tbaf006
Published: 10 April 2025
Image
Binding of BA3011 to cell-surface expressed AXL analyzed by flow cytometry....
Published: 10 April 2025
Figure 2
Binding of BA3011 to cell-surface expressed AXL analyzed by flow cytometry. (A) Concentration-dependent binding of BA3011 to human (top left panel) or cynomolgus AXL (top right panel) expressed on the surface of 293-F cells and cancer cell lines DU145 (bottom left panel) and LCLC103H (bottom right a
Journal Article
ACCEPTED MANUSCRIPT
Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors
Antibody Therapeutics, tbaf004, https://doi.org/10.1093/abt/tbaf004
Published: 18 March 2025
Journal Article
Fundamental properties and principal areas of focus in antibody–drug conjugates formulation development
Antibody Therapeutics, Volume 8, Issue 2, April 2025, Pages 99–110, https://doi.org/10.1093/abt/tbaf005
Published: 09 March 2025
Image
Principal focus points in the ADC drug product development framework.
Published: 09 March 2025
Figure 1
Principal focus points in the ADC drug product development framework.
Image
Specific components for ADC stability and unique technical challenges of AD...
Published: 09 March 2025
Figure 2
Specific components for ADC stability and unique technical challenges of ADC formulation development. (A) ADC stability assessment encompasses multiple critical dimensions: the integrity of the monoclonal antibody (mAb), linker, and payload as individual components, as well as the stability of the f
Journal Article
A systematic review of the avian antibody (IgY) therapeutic effects on human bacterial infections over the decade
Antibody Therapeutics, Volume 8, Issue 2, April 2025, Pages 111–123, https://doi.org/10.1093/abt/tbaf007
Published: 09 March 2025
Image
In vivo models of IgY studies based on different bacterial infecti...
Published: 09 March 2025
Figure 1
In vivo models of IgY studies based on different bacterial infections.
Image
The PRISMA flow diagram of the study search of databases.
Published: 09 March 2025
Figure 2
The PRISMA flow diagram of the study search of databases.
Image
Therapeutic effects of IgY on various bacterial infections.
Published: 09 March 2025
Figure 3
Therapeutic effects of IgY on various bacterial infections.
Journal Article
Fc gamma receptor polymorphisms in antibody therapy: implications for bioassay development to enhance product quality
Antibody Therapeutics, Volume 8, Issue 2, April 2025, Pages 87–98, https://doi.org/10.1093/abt/tbaf003
Published: 21 January 2025
Image
Therapeutic mAbs can mediate cell death through mechanisms involving their ...
Published: 21 January 2025
Figure 1
Therapeutic mAbs can mediate cell death through mechanisms involving their Fc region, specifically ADCC, ADCP, and CDC. In ADCC, the mAb binds to an antigen on the target cell and interacts with FcγRs on an immune cell. This interaction leads to the phosphorylation of ITAM, triggering intracellular
Image
Functional assessment for therapeutic IgG mAbs involves five key aspects. (...
Published: 21 January 2025
Figure 2
Functional assessment for therapeutic IgG mAbs involves five key aspects. (i) Antigen binding affinity or kinetics is evaluated using techniques like SPR, BLI, or ELISA to understand the strength and specificity of antibody interaction with antigens; (ii) cytotoxicity activity is measured through ce
